Influenza viruses are among the most likely triggers of future pandemics. A research team from the Helmholtz Center for Infection Research (HZI) and the Medical Center—University of Freiburg has ...

Montreal-based Nomic Bio broadens its proteomics technology to offer a 1,000-plex protein measurement service.

Methylene blue is FDA-approved to treat a rare blood disorder, but influencers are touting it as a brain and longevity ...

Why antibacterial soaps may disrupt immune learning, raising allergy, autoimmune, and inflammatory disease risks through ...

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability ...

His departure, caused by pneumonia, will always make me to remember my maternal grandmother, an influenza and pneumonia freak ...

Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET. Company Participants. Vincent Anzalone - Vice President of Investor Relatio ...

At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation there ...

Presentations will be available on the Alterity Therapeutics website here.

Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines ...

India already has a homegrown CAR T-cell therapy, and other regions are exploring their own strategies, including developing them at the point of care.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...